Poulvac E. coli

RSS

Escherichia coli aroA gene deleted, type O78, strain EC34195 (live)

Authorised
This medicine is authorised for use in the European Union.

Overview

Poulvac E. coli is a vaccine that is used in chickens and turkeys for active immunisation against an infection caused by Escherichia coli serotype O78, called colibacillosis. Colibacillosis can cause injuries to the sac that surrounds the heart (pericarditis), the sac surrounding the liver (perihepatitis) and the ‘air sacs’, the specialised bags within the bird’s body where air is stored during breathing (airsacculitis), and can lead to death of the bird. The vaccine, which is for use in broiler chickens (reared for meat), future layers or breeders (reared for egg production) and turkeys, helps reduce injuries and deaths caused by the infection.

It contains the live bacteria Escherichia coli, type O78, strain EC34195 with a gene (aroA) deleted.

This EPAR was last updated on 11/02/2022

Authorisation details

Product details
Name
Poulvac E. coli
Agency product number
EMEA/V/C/002007
Active substance
Live aroA gene deleted Escherichia coli, type 078, strain EC34195
International non-proprietary name (INN) or common name
Escherichia coli aroA gene deleted, type O78, strain EC34195 (live)
Species
  • Chicken
  • Turkeys
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AE04
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
15/06/2012
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Product information

09/09/2021 Poulvac E. coli - EMEA/V/C/002007 - II/0018

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

  • Immunologicals for aves

  • Live bacterial vaccines

Therapeutic indication

For active immunisation of broiler chickens and future layers / breeders in order to reduce mortality and lesions (pericarditis, perihepatitis, airsacculitis) associated with Escherichia coli serotype O78.

Assessment history

News

How useful was this page?

Add your rating